Understanding the MAGGIC Risk Model
The MAGGIC score is a validated prognostic tool developed from meta-analysis of 39 cohort studies involving over 108,000 patients with heart failure. Rather than relying on a single measurement, it synthesizes multiple clinical parameters to predict mortality risk. Points are assigned for demographic factors (age, sex), haemodynamic markers (ejection fraction, systolic blood pressure, creatinine), functional status (NYHA class), comorbidities (diabetes, COPD, smoking history), and medication use (ACE inhibitors/ARBs, beta-blockers).
The resulting risk score generates a percentile ranking; higher scores indicate worse prognosis. One critical advantage of this model is its applicability across different heart failure phenotypes—both systolic (reduced ejection fraction) and diastolic (preserved ejection fraction) presentations.
How the MAGGIC Score Is Calculated
The calculator sums points assigned to each clinical variable. Your raw risk score is then converted to 1-year and 3-year survival probabilities using actuarial curves derived from the original cohort. Below is the framework:
Risk Score = Sex + Age + Ejection Fraction + Systolic BP
+ Creatinine + BMI + NYHA Class + ACEi/ARB Use
+ Beta-Blocker Use + Heart Failure History
+ COPD + Current Smoking + Diabetes
1-Year Survival = ƒ(Risk Score)
3-Year Survival = ƒ(Risk Score)
Sex— Male (adds 1 point) or Female (0 points)Age— Years; points increase with age, especially below 30% EFEjection Fraction (EF)— Percentage of blood ejected per beat; lower EF carries higher penaltySystolic BP— Top blood pressure reading (mmHg); risk varies by EF categoryCreatinine— Serum creatinine level (mg/dL); reflects kidney functionBMI— Body mass index (kg/m²); calculated as weight ÷ height²NYHA Class— I (0 pts), II (2 pts), III (6 pts), IV (8 pts); severity of symptomsACEi/ARB— Angiotensin-converting enzyme inhibitor or ARB use (0 pts if yes, 1 if no)Beta-Blocker— Use of beta-blocking medication (0 pts if yes, 3 if no)HF History— Prior heart failure diagnosis or treatment (2 pts if yes, 0 if no)COPD— Chronic obstructive pulmonary disease (2 pts if yes, 0 if no)Smoking— Current smoker status (1 pt if yes, 0 if no)Diabetes— Diabetes mellitus (3 pts if yes, 0 if no)
Heart Failure Stages and Prognosis
The American College of Cardiology and American Heart Association define four stages of heart failure, each with distinct survival characteristics. Understanding your stage is crucial for treatment planning.
Stage A includes high-risk patients without structural heart disease—those with hypertension, diabetes, or prior myocardial infarction. These patients have normal life expectancy with preventive care.
Stage B involves structural changes (e.g., reduced EF, previous MI) but no symptoms. 1-year survival is typically above 95% without disease-modifying therapy.
Stage C presents with both structural disease and symptoms (dyspnoea, fatigue, reduced exercise tolerance). Median survival ranges from 8–10 years, though this varies by EF and comorbidities.
Stage D is advanced, refractory disease requiring specialist intervention. Without transplantation or mechanical support, 1-year survival can drop below 50%. The MAGGIC calculator proves most valuable in stages C and D, where prognostic uncertainty is greatest.
Ejection Fraction and Systolic Heart Failure
Ejection fraction (EF)—the percentage of blood your left ventricle pumps with each contraction—is among the strongest individual predictors of survival. A normal EF is 50–70%; values below 40% define reduced ejection fraction (HFrEF), and below 30% denotes severely reduced function.
In the MAGGIC model, age penalties escalate steeply for patients with EF <30%. For instance, a 75-year-old with EF <30% receives 8 points just for age, whereas the same person with EF 30–39% receives only 6 points. This reflects the non-linear relationship between very low EF and mortality risk.
Mortality in systolic heart failure also depends on medication response. Patients tolerating beta-blockers and ACE inhibitors at target doses have materially better outcomes. The calculator accounts for this by assigning zero points if these medications are used, versus positive points for non-use or intolerance.
Practical Considerations When Using This Calculator
Several factors should inform how you interpret your results.
- Individual Variation Is Substantial — The MAGGIC model predicts population averages, not individual outcomes. Two patients with identical risk scores may have vastly different trajectories based on unmeasured factors (genetic predisposition, medication adherence, acute illness, lifestyle changes). Use the score as one input into a broader clinical discussion, not as a deterministic forecast.
- Recent Hospital Admissions and Acute Decompensation — The MAGGIC cohort was largely stable outpatients. Patients in acute decompensation or within 30 days of hospitalisation often have worse short-term outcomes than the calculator predicts. Reassess after stabilisation and optimisation of therapy.
- Potential for Improvement With Optimal Therapy — The prognostic benefit of modern therapies—including SGLT2 inhibitors, sacubitril/valsartan, and finerenone—were not fully represented in the original MAGGIC studies. If your medications have been recently optimised or upgraded, your actual prognosis may be more favourable than the calculator suggests.
- Age and Comorbidity Burden — Age is a proxy for cumulative comorbidity burden. Younger patients with multiple chronic conditions may not fit the age-risk relationship as cleanly. Similarly, creatinine elevation may reflect chronic kidney disease alone or acute decompensated heart failure with secondary renal impairment—the latter carries worse prognosis.